DexCom Inc. [NASDAQ: DXCM] price plunged by -1.91 percent to reach at -$2.03. The company report on January 24, 2023 that Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a conference call to review the company’s fourth quarter and full year 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.
To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID “9430114” approximately five minutes prior to the start time.
A sum of 3803146 shares traded at recent session while its average daily volume was at 2.72M shares. DexCom Inc. shares reached a high of $105.05 and dropped to a low of $102.50 until finishing in the latest session at $104.00.
The one-year DXCM stock forecast points to a potential upside of 20.1. The average equity rating for DXCM stock is currently 1.70, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on DexCom Inc. [DXCM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DXCM shares is $130.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DXCM stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for DexCom Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on October 18, 2022. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on October 12, 2022, representing the official price target for DexCom Inc. stock. Previously, the target price had yet another raise to $105, while Bernstein analysts kept a Outperform rating on DXCM stock.
The Average True Range (ATR) for DexCom Inc. is set at 3.92, with the Price to Sales ratio for DXCM stock in the period of the last 12 months amounting to 14.16. The Price to Book ratio for the last quarter was 22.22, with the Price to Cash per share for the same quarter was set at 6.24. Price to Free Cash Flow for DXCM in the course of the last twelve months was 151.37 with Quick ratio for the last quarter at 3.40.
DXCM Stock Performance Analysis:
DexCom Inc. [DXCM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.47. With this latest performance, DXCM shares dropped by -8.52% in over the last four-week period, additionally plugging by 25.76% over the last 6 months – not to mention a drop of -2.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DXCM stock in for the last two-week period is set at 38.19, with the RSI for the last a single of trading hit 33.79, and the three-weeks RSI is set at 41.87 for DexCom Inc. [DXCM]. The present Moving Average for the last 50 days of trading for this stock 112.91, while it was recorded at 106.10 for the last single week of trading, and 95.47 for the last 200 days.
Insight into DexCom Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and DexCom Inc. [DXCM] shares currently have an operating margin of +10.86 and a Gross Margin at +68.63. DexCom Inc.’s Net Margin is presently recorded at +6.32.
Return on Equity for this stock inclined to 7.59, with Return on Assets sitting at 3.35.
DexCom Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.80.
DXCM Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DXCM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for DexCom Inc. go to 34.90%.
DexCom Inc. [DXCM] Insider Position Details
There are presently around $37,907 million, or 98.80% of DXCM stock, in the hands of institutional investors. The top three institutional holders of DXCM stocks are: VANGUARD GROUP INC with ownership of 43,682,426, which is approximately 1.185% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 33,609,961 shares of the stock with an approximate value of $3.5 billion in DXCM stocks shares; and BAILLIE GIFFORD & CO, currently with $1.8 billion in DXCM stock with ownership of nearly -4.431% of the company’s market capitalization.
Positions in DexCom Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 405 institutional holders increased their position in DexCom Inc. [NASDAQ:DXCM] by around 20,575,114 shares. Additionally, 383 investors decreased positions by around 57,027,577 shares, while 110 investors held positions by with 286,883,401 shares. The mentioned changes placed institutional holdings at 364,486,092 shares, according to the latest SEC report filing. DXCM stock had 97 new institutional investments in for a total of 3,453,625 shares, while 83 institutional investors sold positions of 2,704,629 shares during the same period.